--Merck Capital Joins Flagship Ventures Backing Leader in Fluorescence In
WOBURN, Mass., Oct. 23 /PRNewswire/ -- VisEn Medical, Inc., a leader in fluorescence in vivo imaging from research through medicine, today announced the completion of its Series B financing. Merck Capital Ventures joined Flagship Ventures to co-lead this $7 million investment round, which also included The Bollard Group and other existing investors. Per Lofberg, President and Chief Executive Officer of Merck Capital Ventures will join VisEn Medical's board of directors.
"I am pleased to have Merck Capital join Flagship Ventures in supporting our company," said Kirtland Poss, President and Chief Executive Officer of VisEn Medical. "We intend to use the proceeds of the Series B financing to expand our sales, marketing and customer support programs, launch additional new products from our technology platforms, and further advance the development of our technologies in clinical imaging applications."
"We look for companies with strong management and proven technology platforms," said Mr. Lofberg of Merck Capital Ventures. "VisEn Medical exemplifies these qualities and has already established a clear leadership position in fluorescence in vivo imaging, a field of growing importance in the pharmaceutical and healthcare industries."
Ed Kania, Chairman of VisEn Medical and Managing Partner of Flagship Ventures noted, "We see tremendous value and promise in VisEn's leading position and close working relationships with top pharmaceutical companies in fluorescence in vivo imaging. We are very pleased to continue our strong support and participation with VisEn in this groundbreaking area."
About VisEn Medical, Inc.
VisEn Medical, Inc. was founded in 2000 based on fluorescence in vivo
imaging technologies initially developed by industry-leading researchers
and clinicians at the Massachusetts General Hospital and Harvar
|SOURCE VisEn Medical, Inc.|
Copyright©2007 PR Newswire.
All rights reserved